• Publications
  • Influence
Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy
TLDR
A selective strategy to kill tumor cells lacking MTAP is described, in which both MTA and a toxic adenine analog, such as 2,6-diaminopurine (DAP), 6-methylpurine (MeP), or 2-fluoroadenine (F-Ade), are administered.
Abstract 5393: Regression of a human T-cell leukemia lacking the methylthioadenosine phosphorylase (MTAP) gene without toxicity of 6-thioguanine (6TG) by pretreatment with methylthioadenosine (MTA)
TLDR
It is demonstrated that MTA completely protects mice bearing MTAP-negative CEM-CCRF human T-cell leukemia from 6TG toxicity while the tumor remains responsive, and marked tumor regression can be obtained without toxicity in tumors lacking MTAP.
Correction: Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy
This sentence (in Discussion section, "Toxicity of MTA in vivo" subsection) contains an incorrect unit and should appear as follows: "MTA has also been administered orally to ten humans at 1,600 mg
A proposed new therapy of tumors deficient in methylthioadenosine phosphorylase (MTAP)
1531 The MTAP gene lies on 9p21 and is often homozygously deleted, along with p16, in tumors -- especially lung and pancreatic cancer, glioma, mesothelioma, and sarcoma (frequency of deletion is